AFX-2
- Generic Name
- AFX-2
Phase 1B- Open Label Dose-Ranging Study of Oral AFX-2 in Adults With Chronic Lymphocytic Leukemia
- First Posted Date
- 2011-10-20
- Last Posted Date
- 2012-01-25
- Lead Sponsor
- Afexa Life Sciences Inc
- Registration Number
- NCT01456182
- Locations
- 🇺🇸
Saint Jospeh Mercy Health System, Ann Arbor, Michigan, United States
🇺🇸Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States
🇺🇸Cancer Center of the Carolinas, Greenville, South Carolina, United States
A Randomized, Double-blind, Placebo-controlled Study on the Effect of CVT-E002 in Patients With Seasonal Allergic Rhinitis
- First Posted Date
- 2008-07-31
- Last Posted Date
- 2010-10-11
- Lead Sponsor
- Afexa Life Sciences Inc
- Target Recruit Count
- 200
- Registration Number
- NCT00726401
- Locations
- 🇨🇦
Melimar Allergy Laboratory, Toronto, Ontario, Canada
🇨🇦JDM Research, Toronto, Ontario, Canada
🇨🇦Capital Health, Edmonton, Alberta, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath